The KEYNOTE-040 trial has shown that a novel immunotherapy treatment can extend the lives of some patients with advanced head and neck cancer for up to 3 years or more.
Find out insider details of the KEYNOTE-048 study in this exclusive interview with first author of the study, Barbara Burtness.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
Among prostate cancer patients, those with DNA mismatch repair mutations have particularly aggressive progression and reduced survivability. Though these tumors are more resistant to traditional treatment methods, a recent study has shown that they may be more susceptible to immunotherapy.
The ground breaking CAR-T therapy – Kymriah® – is set to become the first personalized cancer therapy available on the NHS.
Researchers have demonstrated that artificial intelligence can provide a predictive score for the efficacy of immunotherapy in cancer patients.
Cost–effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.